Adenoviral vaccine targeting multiple neoantigens as strategy to eradicate large tumors combined with checkpoint blockade

Anna Morena D’Alise (), Guido Leoni, Gabriella Cotugno, Fulvia Troise, Francesca Langone, Imma Fichera, Maria De Lucia, Lidia Avalle, Rosa Vitale, Adriano Leuzzi, Veronica Bignone, Elena Di Matteo, Fabio Giovanni Tucci, Valeria Poli, Armin Lahm, Maria Teresa Catanese, Antonella Folgori, Stefano Colloca, Alfredo Nicosia and Elisa Scarselli
Additional contact information
Anna Morena D’Alise: Nouscom Srl
Guido Leoni: Nouscom Srl
Gabriella Cotugno: Nouscom Srl
Fulvia Troise: Nouscom Srl
Francesca Langone: Nouscom Srl
Imma Fichera: Nouscom Srl
Maria De Lucia: Nouscom Srl
Lidia Avalle: University of Turin
Rosa Vitale: Nouscom Srl
Adriano Leuzzi: Nouscom Srl
Veronica Bignone: Nouscom Srl
Elena Di Matteo: Nouscom Srl
Fabio Giovanni Tucci: Nouscom Srl
Valeria Poli: University of Turin
Armin Lahm: Nouscom Srl
Maria Teresa Catanese: Nouscom Srl
Antonella Folgori: Nouscom Srl
Stefano Colloca: Nouscom Srl
Alfredo Nicosia: Nouscom AG, Bäumleingasse, 18 CH-4051
Elisa Scarselli: Nouscom Srl

Nature Communications, 2019, vol. 10, issue 1, 1-12

Abstract: Abstract Neoantigens (nAgs) are promising tumor antigens for cancer vaccination with the potential of inducing robust and selective T cell responses. Genetic vaccines based on Adenoviruses derived from non-human Great Apes (GAd) elicit strong and effective T cell-mediated immunity in humans. Here, we investigate for the first time the potency and efficacy of a novel GAd encoding multiple neoantigens. Prophylactic or early therapeutic vaccination with GAd efficiently control tumor growth in mice. In contrast, combination of the vaccine with checkpoint inhibitors is required to eradicate large tumors. Gene expression profile of tumors in regression shows abundance of activated tumor infiltrating T cells with a more diversified TCR repertoire in animals treated with GAd and anti-PD1 compared to anti-PD1. Data suggest that effectiveness of vaccination in the presence of high tumor burden correlates with the breadth of nAgs-specific T cells and requires concomitant reversal of tumor suppression by checkpoint blockade.

Date: 2019
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-019-10594-2 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:10:y:2019:i:1:d:10.1038_s41467-019-10594-2

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-019-10594-2

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().